
S2 Episode 1: Caught Off Guard? Menopause in MS Deserves Better
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
このコンテンツについて
Join Drs Anne Cross and Riley Bove as they discuss menopause in multiple sclerosis, including overlapping symptoms, hormone therapy, and why this transition shouldn't catch anyone off guard.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002583. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Hormonal Therapies in Multiple Sclerosis: A Review of Clinical Data https://pubmed.ncbi.nlm.nih.gov/38102502/
The 2022 Hormone Therapy Position Statement of The North American Menopause Society https://pubmed.ncbi.nlm.nih.gov/35797481/
Age-Specific Effects of Hormone Therapy Use on Overall Mortality and Ischemic Heart Disease Mortality Among Women in the California Teachers Study https://pubmed.ncbi.nlm.nih.gov/20881652/
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT https://pubmed.ncbi.nlm.nih.gov/36734148/
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial https://pubmed.ncbi.nlm.nih.gov/12117397/
Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review https://pubmed.ncbi.nlm.nih.gov/33815241/
Uhthoff's Phenomenon in Multiple Sclerosis and Neuromyelitis Optica https://pubmed.ncbi.nlm.nih.gov/25195501/
Molecular Basis of Klotho: From Gene to Function in Aging https://pubmed.ncbi.nlm.nih.gov/25695404/
Re-WRAP (Remyelination for Women at Risk of Axonal Loss and Progression): A Phase II Randomized Placebo-Controlled Delayed-Start Trial of Bazedoxifene for Myelin Repair in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/37739167/
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial https://pubmed.ncbi.nlm.nih.gov/29029896/